"Oncology is hot" is true and useless. It's roughly 41% of our radar — far too coarse to do anything with — a number that big isn't a signal, it's a category. The value is in the zoom. When you look inside the oncology block, it resolves into a handful of concrete, nameable races, plus a subtler signal one level down that most competitive-intelligence tools miss entirely.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
What a kinase inhibitor actually does
To read these races you have to know what the molecules are for. Kinases are enzymes that switch other proteins on and off by attaching a phosphate group borrowed from ATP, the cell's energy currency. That single reaction — phosphorylation — is one of biology's master switches: it drives the signaling cascades that tell a cell to grow, divide, survive, or mount an immune response. When one of those switches gets stuck on — a mutated, hyperactive kinase — the result can be a tumor or a runaway immune process. Block the kinase and you interrupt the signal at its source.
Almost all small-molecule kinase inhibitors do this the same way: they wedge into the pocket where ATP normally binds and compete it out. The catch is that the human genome encodes hundreds of kinases, and the ATP pocket is one of the most conserved structures across all of them. A drug that fits one pocket tends to fit many, and hitting the wrong ones causes toxicity. So the entire discipline of kinase medicinal chemistry is a hunt for selectivity — exploiting the small differences in shape and the handful of non-conserved amino acids that ring each target's pocket. Every EGFR and BTK molecule on the radar is a different answer to that same problem. And, as we'll see, the answers keep expiring.
Two races you can name
The first is EGFR — a mature but ferociously competitive lung-cancer target, and one of the most active clusters on the board. Its standout molecule climbed from near-zero for a simple reason: in August 2024 the FDA approved it (as Lazcluze, with amivantamab) as a first-line, chemotherapy-free regimen for EGFR-mutated lung cancer, beating the prior standard of care on progression-free survival. [1] An approval like that doesn't just create a drug; it validates a whole line of chemistry and pulls competitors, manufacturers, and suppliers toward the same target.
The second is BTK, and this is where the radar earns its keep as a leading indicator. BTK began as a blood-cancer target and is now expanding into immunology — and we see both the incumbent and the expansion play accelerating together. The expansion molecule's timing is the tell: in November 2025, Genentech reported it as the first BTK inhibitor to hit its primary endpoint in Phase 3 for both relapsing and primary-progressive multiple sclerosis. [2] When a target class's incumbent and its expansion play rise at the same time, you're watching it broaden its addressable market in real time — a very different signal from any single approval.
Why these races never end: the resistance treadmill
Both stories are driven by the same engine: a target mutates its way out of every drug, and the next generation is built to chase it. EGFR inhibitors began as reversible binders; tumors escaped by acquiring a gatekeeper mutation (T790M) that restored the target's grip on ATP and shut the drugs out. A third generation was then engineered to hit that mutant selectively while sparing the healthy version of the protein. Predictably, tumors are now escaping the third generation with yet another mutation (C797S), and a fourth generation is in the works to answer it. Each turn of that wheel is a new molecule, a new patent estate, and fresh demand for the chemistry behind it.
BTK shows the same pattern from a different angle. The first inhibitors were covalent: they form a permanent chemical bond to a specific cysteine amino acid sitting in the target's ATP pocket. That works beautifully — until the cysteine itself mutates and the anchor point disappears. The escape route is essentially the same as EGFR's: lose the residue the drug was built to grab, and the drug is finished. The industry's answer, once again, is a new generation built on a different binding strategy entirely. Resistance, in these markets, isn't a bug. It's the thing that keeps the demand renewing.
Covalent, reversible, and the jump into immunology
That difference in binding strategy is worth dwelling on, because it explains much of what the radar shows. A covalent inhibitor's permanent bond gives it real advantages: deep and durable target suppression, high potency, and selectivity that comes almost for free, since it latches onto a residue few other proteins share. The price is fragility — the whole approach hinges on one amino acid, so a single mutation there ends it, and permanent bonds carry their own long-tail safety questions. Reversible, non-covalent inhibitors like fenebrutinib bind and release instead of latching. They don't depend on that vulnerable cysteine, so they keep working where the covalent drugs fail, and they can be tuned to reach tissues the earlier drugs couldn't — including the central nervous system.
That reach is what turns a resistance workaround into a market event. A cancer target is bounded by the number of patients with that specific tumor. But a kinase like BTK sits at the center of immune signaling, so the same mechanism that fought a blood cancer can be pointed at chronic autoimmune and inflammatory disease — conditions that affect far larger populations and are treated for years rather than months. When a target class broadens out of a narrow oncology niche into chronic immunology, its addressable demand doesn't grow incrementally; it multiplies, and the character of that demand shifts from episodic to sustained. That is why an incumbent and an expansion play rising together is a more interesting signal than either one alone.
The layer almost nobody sees
Here's the part almost no one surfaces. The single fastest-accelerating entry on the entire radar this week isn't a drug at all — it's a molecular scaffold, one of the heterocyclic cores medicinal chemists build kinase inhibitors from. These cores are the reusable chassis of the field: a ring system that fits the ATP pocket, onto which chemists hang the pieces that tune potency, selectivity, and drug-like behavior. A single good scaffold can seed an entire series of candidates.
That's why scaffold-level activity runs upstream of the named-drug surge. Before there is a clinical candidate with a name, there are chemists working around a promising core — ordering building blocks, making analogs, screening variations. A surge there is the bench itself lighting up, one step before the programs it will feed become public. If EGFR and BTK are where the market is today, the scaffold signal is a peek at where it is being built.
Three layers, three buyers
That's the whole reason to read oncology this way instead of tracking drug names: the three layers map cleanly onto three different customers. The named molecules are API-sourcing and manufacturing signals. For contract manufacturers and API suppliers, an approval or a late-stage readout tells them where clinical and commercial volume is about to be needed — and a target moving from episodic oncology into chronic immunology tells them that volume will be larger and steadier than an oncology label alone would imply.
The same named-molecule layer is a competitive-intelligence signal for the strategy and business-development teams inside pharma: who is crowding onto a target, which generation the race has reached, and which resistance mutation the next wave is being built to defeat. Read that early and it shapes licensing, partnering, and go/no-go decisions before the field is obvious.
The scaffold surge belongs to a third buyer entirely: the building-block, reagent, and screening-library suppliers who sell the raw material of discovery. A rising core means demand for specific intermediates and analog sets before any drug program announces itself — the earliest commercial signal in the chain, and the one furthest from the headlines. Three observations, three buyers, one line running from science to sale. Which specific molecules, scaffolds, and buyers sit in each layer is the board itself — and that's the part we keep.
What the signal doesn't tell you
None of this is a license to pile in. A hot target is a crowded one, and the same forces that put EGFR and BTK on the board have drawn many competitors toward them; late entrants can arrive to a saturated field and thin economics. Presence on the radar tells you where attention and effort are concentrating, not whether there is room left to make money.
The resistance treadmill cuts both ways, too. The mutation that renews demand for the next generation can also undercut the current one faster than anyone planned, compressing the commercial window a molecule was supposed to enjoy. And for every generation of a target, only a few candidates survive the clinic — a scaffold lighting up is chemists placing bets, not a drug that will exist. These are directional, upstream reads: they point at where the science is pushing and where the money is likely to follow, early enough to be useful and rough enough to demand judgment. That is exactly the trade the radar is built to make — sooner and coarser, rather than certain and late.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.